Sanofi, Gustave Roussy, l’Inserm, l’Institut Polytechnique de Paris et l’Université Paris-Saclay s’engagent pour faire émerger en France une médecine personnalisée à travers un cluster en oncologie centré sur le patient : le Paris Saclay Cancer Cluster.

Paris and Lyon, on June 16, 2021

Quality Office

Gustave Roussy clinical research is organized to enhance its performance, to develop its ability to manage large national and international academic trials with high added value and to strengthen Gustave Roussy position as a preferred innovative trials platform for pharma companies.

Clinical Operations Unit

As an Investigator site, Gustave Roussy has a Clinical Operations Unit ensuring clinical research activities for all therapeutic trials and clinical studies.  This service is provided regardless of the sponsor category (pharma industries, biotech, scientific associations, academic institutions), at all development phases (from early to advanced phase) including strategic areas such as Molecular Medicine, Antitumor Immunology, DNA repair and rare Cancers.

Le 10 juin 2021

The international meeting of the American Society of Clinical Oncology (ASCO) gathers every year the world’s leading cancer experts. In 2021, ASCO meeting is virtual. Oral, Poster Discussion, and Poster Sessions, as well as track-based Clinical Science Symposia, are available on ASCO's website.

Le 2 Juin 2021

ASCO 2021

Metastatic or recurrent cancer of the uterine cervix: Encouraging results with second generation immunotherapy

An early trial presented by the Institut Bergonié and Gustave Roussy at the 2021 ASCO Conference shows that patients with metastatic or recurrent cancer of the cervix may benefit from dual immunotherapy. The new generation agent, Simlukafusp Alfa, a variant of interleukin-2, shows promising signs of efficacy by doubling the response to anti-PD-L1 immunotherapy alone, without causing major adverse effects.